Multivalent Tranexamic Acid (TXA) and Benzamidine Derivatives for Serine Protease Inhibition

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Blood coagulation and fibrinolysis are critical hemostatic processes regulated by serine proteases.
• Imbalances in hemostasis can lead to severe bleeding or thrombotic conditions, necessitating therapeutic interventions.

Purpose of the Study:

• To synthesize and evaluate heterobivalent molecules combining benzamidine and tranexamic acid (TXA) for inhibiting key proteases in hemostasis.
• To investigate the impact of varying linker lengths on inhibitor efficacy against plasmin, thrombin, and tissue plasminogen activator (tPA).

Main Methods:

• Synthesis of heterobivalent molecules with dPEG linkers of varying lengths (dPEG4-dPEG36).
• Enzymatic assays using soluble substrates to determine inhibition constants (Ki) and IC50 values.
• Evaluation of inhibitor effects on fluorescently tagged fibrin clots to assess fibrinolytic potential.

Main Results:

• Inhibitor efficacy against plasmin and tPA increased with linker lengths exceeding the separation of active and lysine binding sites, attributed to multivalent binding.
• Homomultivalent TXA demonstrated potent competitive inhibition of plasmin (Ki = 2.5 ± 1.8 μM) via statistical rebinding.
• IC50 values on fibrin clots provided insights into kringle binding inhibition's effect on fibrinolysis.

Conclusions:

• Tailoring linker length in heterobivalent inhibitors can optimize the inhibition of serine proteases involved in hemostasis.
• Multivalent binding and statistical rebinding are effective strategies for enhancing protease inhibition.
• These findings contribute to the development of novel therapeutics for hemostatic disorders.